Publisher
Springer Science and Business Media LLC
Reference14 articles.
1. Dimopoulos, M. A. et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 17, 27–38 (2016).
2. Stewart, A. K. et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 372, 142–152 (2015).
3. Siegel, D. et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 98, 1753–1761 (2013).
4. Chari, A. & Hajje, D. Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring. BMC Cancer. 14, 915 (2014).
5. Rosenthal, A. et al. Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? Blood Cancer J. 6, e384 (2016).
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献